Getinge AB (publ) (GETI-B.ST)
SEK 174.85
(2.01%)
SEK 174.85
(2.01%)
| Year | Eps | Eps Growth |
|---|---|---|
| 2023 | 8.86 SEK | -3.17% |
| 2022 | 9.15 SEK | -16.06% |
| 2021 | 10.90 SEK | -8.33% |
| 2020 | 11.89 SEK | 164.81% |
| 2019 | 4.49 SEK | 226.48% |
| 2018 | -3.55 SEK | -164.66% |
| 2017 | 5.49 SEK | 11.81% |
| 2016 | 4.91 SEK | -10.73% |
| 2015 | 5.50 SEK | -3.0% |
| 2014 | 5.67 SEK | -37.28% |
| 2013 | 9.04 SEK | -9.42% |
| 2012 | 9.98 SEK | -0.2% |
| 2011 | 10.00 SEK | 11.11% |
| 2010 | 9.00 SEK | 19.05% |
| 2009 | 7.56 SEK | 10.85% |
| 2008 | 6.82 SEK | 23.77% |
| 2007 | 5.51 SEK | -2.65% |
| 2006 | 5.66 SEK | 10.12% |
| 2005 | 5.14 SEK | -0.96% |
| 2004 | 5.19 SEK | 47.86% |
| 2003 | 3.51 SEK | 24.91% |
| 2002 | 2.81 SEK | 0.0% |
| Year | Eps | Eps Growth |
|---|---|---|
| 2024 Q2 | 1.88 SEK | 11.24% |
| 2024 Q3 | 0.01 SEK | -99.61% |
| 2024 Q1 | 1.69 SEK | -35.98% |
| 2023 Q1 | 2.15 SEK | 5.39% |
| 2023 Q4 | 2.64 SEK | -19.51% |
| 2023 Q3 | 3.28 SEK | 315.19% |
| 2023 Q2 | 0.79 SEK | -63.26% |
| 2023 FY | - SEK | -3.17% |
| 2022 Q2 | 2.21 SEK | 12.76% |
| 2022 Q1 | 1.96 SEK | -31.23% |
| 2022 FY | - SEK | -16.06% |
| 2022 Q4 | 2.04 SEK | -30.38% |
| 2022 Q3 | 2.93 SEK | 32.58% |
| 2021 Q1 | 2.36 SEK | -41.29% |
| 2021 FY | - SEK | -8.33% |
| 2021 Q2 | 2.93 SEK | 24.15% |
| 2021 Q3 | 2.78 SEK | -5.12% |
| 2021 Q4 | 2.85 SEK | 2.52% |
| 2020 Q3 | 5.07 SEK | 180.11% |
| 2020 FY | - SEK | 164.81% |
| 2020 Q2 | 1.81 SEK | 81.0% |
| 2020 Q1 | 1.00 SEK | -69.88% |
| 2020 Q4 | 4.02 SEK | -20.71% |
| 2019 Q4 | 3.32 SEK | 336.84% |
| 2019 Q3 | 0.76 SEK | 100.0% |
| 2019 Q1 | 0.02 SEK | -99.24% |
| 2019 FY | - SEK | 226.48% |
| 2019 Q2 | 0.38 SEK | 1800.0% |
| 2018 Q3 | -5.34 SEK | -1880.0% |
| 2018 FY | - SEK | -164.66% |
| 2018 Q1 | -1.13 SEK | -126.65% |
| 2018 Q2 | 0.30 SEK | 126.55% |
| 2018 Q4 | 2.62 SEK | 149.06% |
| 2017 Q4 | 4.24 SEK | 2020.0% |
| 2017 Q3 | 0.20 SEK | 1900.0% |
| 2017 FY | - SEK | 11.81% |
| 2017 Q2 | 0.01 SEK | -99.13% |
| 2017 Q1 | 1.15 SEK | -69.09% |
| 2016 Q4 | 3.72 SEK | 1133.33% |
| 2016 Q1 | 0.43 SEK | -88.65% |
| 2016 Q2 | 0.88 SEK | 104.65% |
| 2016 FY | - SEK | -10.73% |
| 2016 Q3 | -0.36 SEK | -140.91% |
| 2015 FY | - SEK | -3.0% |
| 2015 Q4 | 3.79 SEK | 449.28% |
| 2015 Q3 | 0.69 SEK | 2.99% |
| 2015 Q2 | 0.67 SEK | 86.11% |
| 2015 Q1 | 0.36 SEK | -90.91% |
| 2014 Q1 | -1.31 SEK | -126.84% |
| 2014 FY | - SEK | -37.28% |
| 2014 Q4 | 3.96 SEK | 173.1% |
| 2014 Q3 | 1.45 SEK | -7.64% |
| 2014 Q2 | 1.57 SEK | 219.85% |
| 2013 Q4 | 4.88 SEK | 199.39% |
| 2013 FY | - SEK | -9.42% |
| 2013 Q3 | 1.63 SEK | -9.44% |
| 2013 Q2 | 1.80 SEK | 150.0% |
| 2013 Q1 | 0.72 SEK | -82.73% |
| 2012 Q2 | 2.09 SEK | 25.9% |
| 2012 Q3 | 2.05 SEK | -1.91% |
| 2012 Q4 | 4.17 SEK | 103.41% |
| 2012 FY | - SEK | -0.2% |
| 2012 Q1 | 1.66 SEK | -62.27% |
| 2011 Q3 | 2.02 SEK | 5.76% |
| 2011 FY | - SEK | 11.11% |
| 2011 Q1 | 1.65 SEK | -53.13% |
| 2011 Q4 | 4.40 SEK | 117.82% |
| 2011 Q2 | 1.91 SEK | 15.76% |
| 2010 Q3 | 1.96 SEK | 2.08% |
| 2010 Q2 | 1.92 SEK | 21.52% |
| 2010 Q1 | 1.58 SEK | -49.36% |
| 2010 FY | - SEK | 19.05% |
| 2010 Q4 | 3.52 SEK | 79.59% |
| 2009 FY | - SEK | 10.85% |
| 2009 Q3 | 1.62 SEK | 24.62% |
| 2009 Q4 | 3.12 SEK | 92.59% |
| 2009 Q1 | 1.51 SEK | 0.0% |
| 2009 Q2 | 1.30 SEK | -13.91% |
| 2008 FY | - SEK | 23.77% |
| 2007 FY | - SEK | -2.65% |
| 2006 FY | - SEK | 10.12% |
| 2005 FY | - SEK | -0.96% |
| 2004 FY | - SEK | 47.86% |
| 2003 FY | - SEK | 24.91% |
| 2002 FY | - SEK | 0.0% |
| Name | Eps | Eps Difference |
|---|---|---|
| Acarix AB (publ) | -0.16 SEK | 5637.5% |
| ADDvise Group AB (publ) | 0.56 SEK | -1482.143% |
| ADDvise Group AB (publ) | 0.56 SEK | -1482.143% |
| Arcoma AB | 0.19 SEK | -4563.158% |
| Bactiguard Holding AB (publ) | -3.95 SEK | 324.304% |
| BICO Group AB (publ) | -12.99 SEK | 168.206% |
| Boule Diagnostics AB (publ) | 0.64 SEK | -1284.375% |
| CellaVision AB (publ) | 5.46 SEK | -62.271% |
| Clinical Laserthermia Systems AB (publ) | -23.76 SEK | 137.29% |
| Chordate Medical Holding AB (publ) | -0.13 SEK | 6915.385% |
| C-Rad AB (publ) | 1.05 SEK | -743.81% |
| Duearity AB (publ) | -0.40 SEK | 2315.0% |
| Dignitana AB (publ) | -0.25 SEK | 3644.0% |
| Episurf Medical AB (publ) | -0.36 SEK | 2561.111% |
| Scandinavian Real Heart AB (Publ) | -0.70 SEK | 1365.714% |
| Iconovo AB (publ) | -4.39 SEK | 301.822% |
| Integrum AB (publ) | 0.23 SEK | -3752.174% |
| Luxbright AB (publ) | -0.37 SEK | 2494.595% |
| Mentice AB (publ) | -0.11 SEK | 8154.545% |
| OssDsign AB (publ) | -1.59 SEK | 657.233% |
| Paxman AB (publ) | 0.44 SEK | -1913.636% |
| Promimic AB (publ) | -0.50 SEK | 1872.0% |
| Qlife Holding AB (publ) | -526.52 SEK | 101.683% |
| SciBase Holding AB (publ) | -0.51 SEK | 1837.255% |
| ScandiDos AB (publ) | -0.32 SEK | 2868.75% |
| Sectra AB (publ) | 2.22 SEK | -299.099% |
| Sedana Medical AB (publ) | -0.60 SEK | 1576.667% |
| Senzime AB (publ) | -1.45 SEK | 711.034% |
| SpectraCure AB (publ) | -0.21 SEK | 4319.048% |
| Stille AB | 5.31 SEK | -66.855% |
| Vitrolife AB (publ) | -28.44 SEK | 131.153% |
| Xvivo Perfusion AB (publ) | 3.07 SEK | -188.599% |